News for Healthier Living

Researchers Report First Published Case of a Patient with Treatment-Emergent Neuroendocrine Prostate Cancer Who Showed a Remarkable Response to an Anti-HER2 Antibody-Drug Conjugate

A new case report published in Annals of Internal Medicine describes the success of human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in a patient with HER2-expressing treatment-emergent neuroendocrine prostate cancer (t-NEPC).

November 4, 2024


November 12 2024

November 11 2024

November 10 2024

November 9 2024

November 8 2024

November 7 2024

November 6 2024

November 5 2024

November 4 2024

November 3 2024

November 2 2024

November 1 2024

October 31 2024

October 30 2024